NeOnc Technologies To Present Data From Intranasal NEO100 And Oral NEO212 Programs In Two Posters, At 31st Annual Meeting And Education Day Of SNO

NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that data from its intranasal NEO100 and oral NEO212 programs will be presented in two posters on Friday, November 13, at the 31st Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), held November 12 to 15, 2026, at the Pennsylvania Convention Center in Philadelphia.